BioSpace News Archive

American Regent today announced the introduction of Selenious Acid Injection, USP.

$1 million grant partnership will expand the number of care providers to engage more than 250 patients with substance abuse addiction per year

Scientists have identified a new ally in the battle against the deadly outbreak of the superbug Candida auris, currently found in more than 20 countries and likely spreading.

Responding to the growth of the global point-of-care (POC) diagnostics market, which is projected to exceed $38 billion by 2022 (MarketsandMarkets™), Cambridge Healthtech Institute will expand opportunities to explore POC innovations during its eleventh annual Next Generation Dx Summit, taking place August 20-22, 2019 in Washington, DC.

The new revolutionary energy-based facial and body treatment designed to create new elastin, collagen and hyaluronic acid is now at Schweiger Dermatology Group.

Acutus Medical today announced the appointment of Scott Huennekens as Executive Chairman of the Board of Directors.

Cantel Medical Corp. (NYSE: CMD) announced today that Eric Nodiff, Executive Vice President, General Counsel and Secretary, will be retiring on July 31, 2019 after 32 years of service to the Company and Jeff Mann has been appointed as Senior Vice President, General Counsel and Secretary, effective August 1, 2019.

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5.XE), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, is pleased to report that its partner Zambon S.p.A. and Valeo Pharma Inc. announced today the launch of Onstryv® (safinamide) for the treatment of Parkinson’s disease in Canada.

JDRF, the leading global organization funding type 1 diabetes (T1D) research, today brought leading voices in the T1D community, including more than 160 children with the disease, to Washington to urge Congress to renew the Special Diabetes Program.

Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of solid tumors, today announces it has received the approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to proceed with a Phase 1 clinical trial of its lead myvacTM candidate TG4050.